drugset / Trial / NCT01287338

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

NCT01287338 ↗

Phase 2 Terminated 143 enrolled Mati Therapeutics Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to test if olopatadine punctal plugs can reduce the symptoms (itching) of allergic conjunctivitis to ragweed in an Environmental Exposure Chamber model.

Timeline

Start
2010-10
Primary completion
2011-01
Completion
2011-01

Outcome

Outcome not reported

Stopped: “Lack of definitive clinical results.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Olopatadine Other / unclassified — —

Indications